Female Urology

The company expects the device to become available for US patients with pelvic organ prolapse in September 2024.

There were no differences in the number of treatment-related TEAEs in patients who received sildenafil cream vs patients who received placebo.

In this episode of Speaking of Urology®, Ashley G. Winter, MD, discusses the use of vaginal estrogen.

"You have to have a passion for it. If you have a passion for it, it's easy to do," says Shaya Taghechian, MD.

"I think pelvic pain is 1 of the areas that really needs more attention," says Gamal M. Ghoniem, MD, FACS, ABU/FPMRS.

"There is a severe lack of treatment when it comes to women's sexual health," says Shaya Taghechian, MD.

"When looking at individual vaginal estrogen products prescribed by OB-GYNs median spending per claim for Vagifem and Yuvafem decreased and median spending per claim increased for Estrace and Estring," says Alexandra Tabakin, MD.

Developed by the AUGS Scientific Committee and Research Agenda Writing Group

"Every time I leave the meeting, I just feel reinvigorated, refreshed, and excited about this field that we're a part of," says Raveen Syan, MD, FPMRS.

"I don't think 1 database study creates dogma, but I do think we can share these data with our patients and talk to them about treatment options and risk, have that difficult conversation about how BMI may be associated with that risk," says Cassandra K. Kisby, MD, MS.

"The most important thing that I think came out of this study is really the BMI inflection point for complications. We saw an abrupt rise in complications around a BMI of 40," says Cassandra K. Kisby, MD, MS.

The FDA approval is supported by data from the phase 3 ALLIUM trial, which demonstrated the non-inferiority and superiority of cefepime/enmetazobactam vs piperacillin/tazobactam.

The aim of this document is to present a framework by which AUGS and its members can address the development of new technology and techniques, particularly in the surgical arena.

The FDA has issued a complete response letter regarding a new drug application for cefepime-taniborbactam for the treatment of patients with complicated urinary tract infection.

The position statement is meant to iterate AUGS' support for gender inclusion of both patients and health care providers.

Cefepime-taniborbactam is currently under review by the FDA for cUTI, including acute pyelonephritis, based on data from the CERTAIN-1 trial.

The purpose of this clinical consensus statement is to identify areas of expert consensus and nonconsensus regarding pessary fitting, follow-up, and management of pessary complications to improve the safety and quality of care where evidence is currently limited.

Iterum plans to resubmit a New Drug Application for oral sulopenem for the treatment of patients with uUTi in Q2 of 2024.

The goals of the American Urogynecologic Society (AUGS) program are to support novel clinical, translational, and bench research pilot projects and enable early career investigators to obtain future independent funding for research.

There are several new CPT codes for 2024, including Category III codes for tibial nerve stimulation and other changes to codes in the treatment of urinary incontinence.

NRX-101 is a fixed-dose combination of the broad-spectrum antibiotic D-cycloserine and lurasidone.

“The bladder muscle can get weak as you get older, so developing urinary incontinence or ur-gency is very common as you get older,” says Vikas Desai, MD.

Amy Luckenbaugh, MD, is an assistant professor of Urology at Vanderbilt University Medical Center.

The IND clearance will initiate a phase 2 registrational study to investigate the safety and efficacy of NRX-101 in patients with complicated UTIs.

“I think being younger and going through something so scary, I think it's been really important to her to have someone with her throughout the whole process,” says Bree Duncan, RN, BSN.